(HealthDay)—The U.S. Food and Drug Administration has approved ribociclib (Kisqali) in combination with an aromatase inhibitor (AI) as an initial
Continue reading »
mypharmacynews.com
(HealthDay)—The U.S. Food and Drug Administration has approved ribociclib (Kisqali) in combination with an aromatase inhibitor (AI) as an initial
Continue reading »Aromatase inhibitors are commonly used in the treatment of hormone-sensitive breast cancer. Though effective, they produce unpleasant side effects that
Continue reading »A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor (EGFR), a cell surface
Continue reading »A multinational collaboration of researchers found that efavirenz, the key component of the most commonly used HIV cocktail in the
Continue reading »On June 12, the American Medical Association announced that drug shortages pose an urgent public health crisis. This crisis should
Continue reading »A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance
Continue reading »New research from a Swedish and Norwegian team of researchers led from Karolinska Institutet does not support a suggested link
Continue reading »Research published in Addiction Biology by scientists at the University of Bath reveals a new potential mechanism for combatting drug
Continue reading »A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS)
Continue reading »One of the world’s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and
Continue reading »